Мезенхимальные стволовые клетки в регенеративной терапии: Терапевтический потенциал и области применения
Ключевые слова:
мезенхимальные стволовые клетки, регенеративная клеточная терапия, МСК косного мозга, плацентарные мезенхимальные стволовые клеткиАннотация
Цель данного обзора - представить обновленную информацию о потенциале использования мезенхимальных стволовых клеток (МСК) в регенеративной медицине. МСК могут быть выделены из различных тканей организма, при этом их биологические свойства во многом зависят от источника происхождения. МСК костного мозга остаются наиболее изученными и широко применяемыми, однако их использование ограничено инвазивностью получения, низким клеточным выходом и возраст-зависимым снижением регенераторного потенциала. Плацента человека является альтернативным источником МСК для исследования и разработки препаратов благодаря высокой доступности, возможности получения большого количества клеток и низкой иммуногенности. Настоящий обзор направлен на обобщение современных литературных данных о регенеративных свойствах мезенхимальных стволовых клеток костного мозга и плаценты человека и сравнительную оценку их потенциала для применения в регенеративной медицине.
Скачивания
Библиографические ссылки
Koltsova, A. M., Zenin, V. V., Petrosyan, M. A., Turilova, V. I., Yakovleva, T. K., Poljanskaya, G. G. (2021). Isolation and characterization of mesenchymal stem cells derived from different regions of the placenta of the same donor. Cell and Tissue Biology, 15(4), 356-369. https://doi.org/10.1134/S1990519X21040040
Schmelzer, E., McKeel, D. T., Gerlach, J. C. (2019). Characterization of human mesenchymal stem cells from different tissues and their membrane encasement for prospective transplantation therapies. BioMed Research International, 2019(1), 6376271. https://doi.org/10.1155/2019/6376271
Silini, A. R., Magatti, M., Cargnoni, A., Parolini, O. (2017). Is immune modulation the mechanism underlying the beneficial effects of amniotic cells and their derivatives in regenerative medicine?. Cell transplantation, 26(4), 531-539. https://doi.org/10.3727/096368916X693699
Metheny, L., Eid, S., Lingas, K., Ofir, R., Pinzur, L., Meyerson, H., Huang, A. Y. (2018). Posttransplant intramuscular injection of PLX-R18 mesenchymal-like adherent stromal cells improves human hematopoietic engraftment in a murine transplant model. Frontiers in Medicine, 5, 37. https://doi.org/10.3389/fmed.2018.00037
Deng, X., Zhang, S., Qing, Q., Wang, P., Ma, H., Ma, Q., Lu, M. (2024). Distinct biological characteristics of mesenchymal stem cells separated from different components of human placenta. Biochemistry and Biophysics Reports, 39, 101739. https://doi.org/10.1016/j.bbrep.2024.101739
Moonshi, S. S., Adelnia, H., Wu, Y., Ta, H. T. (2022). Placenta‐derived mesenchymal stem cells for treatment of diseases: a clinically relevant source. Advanced Therapeutics, 5(10), 2200054. https://doi.org/10.1002/adtp.202200054
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Marshak, D. R. (1999). Multilineage potential of adult human mesenchymal stem cells. science, 284(5411), 143-147. https://doi.org/10.1126/science.284.5411.143
Centurione, L., Passaretta, F., Centurione, M. A., De Munari, S., Vertua, E., Silini, A., Di Pietro, R. (2018). Mapping of the human placenta: experimental evidence of amniotic epithelial cell heterogeneity. Cell Transplantation, 27(1), 12-22. https://doi.org/10.1177/0963689717725078
Papait, A., Vertua, E., Magatti, M., Ceccariglia, S., De Munari, S., Silini, A. R., Parolini, O. (2020). Mesenchymal stromal cells from fetal and maternal placenta possess key similarities and differences: potential implications for their applications in regenerative medicine. Cells, 9(1), 127. https://doi.org/10.3390/cells9010127
Friedenstein, A. J., Piatetzky-Shapiro, I. I., Petrakova, K. V. (1966). Osteogenesis in transplants of bone marrow cells. Development, 16(3), 381-390. https://doi.org/10.1242/dev.16.3.381
Owen, M., & Friedenstein, A. J. (2007, September). Stromal stem cells: Marrow‐derived osteogenic precursors. In Ciba Foundation Symposium 136‐Cell and Molecular Biology of Vertebrate Hard Tissues: Cell and Molecular Biology of Vertebrate Hard Tissues: Ciba Foundation Symposium 136 (pp. 42-60). Chichester, UK: John Wiley & Sons, Ltd.. https://doi.org/10.1002/9780470513637.ch4
Caplan, A. I. (1991). Mesenchymal stem cells. Journal of orthopaedic research, 9(5), 641-650. https://doi.org/10.1002/jor.1100090504
Robey, P. (2017). “Mesenchymal stem cells”: fact or fiction, and implications in their therapeutic use. F1000Research, 6, F1000-Faculty. https://doi.org/10.12688/f1000research.10955.1
Dominici, M. L. B. K., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., ... & Horwitz, E. M. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-317. https://doi.org/10.1080/14653240600855905
Trigo CM, Rodrigues JS, Camões SP, Solá S, Miranda JP. Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? J Adv Res. 2025 Apr;70:103-124. https://doi.org/10.1016/j.jare.2024.05.004
Lyu, Z., Xin, M., Oyston, D. R., Xue, T., Kang, H., Wang, X., Li, Q. (2024). Cause and consequence of heterogeneity in human mesenchymal stem cells: challenges in clinical application. Pathology-Research and Practice, 260, 155354. https://doi.org/10.1016/j.prp.2024.155354
Česnik, A. B., Švajger, U. (2024). The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review. Frontiers in Cell and Developmental Biology, 12, 1400347. https://doi.org/10.3389/fcell.2024.1400347
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., ... & Vizoso, F. J. (2021). Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cellular and Molecular Life Sciences, 78(2), 447-467. https://doi.org/10.1007/s00018-020-03600-0
Zhu, X., Xu, X., Shen, M., Wang, Y., Zheng, T., Li, H., Meng, J. (2023). Transcriptomic heterogeneity of human mesenchymal stem cells derived from bone marrow, dental pulp, adipose tissue, and umbilical cord. Cellular Reprogramming, 25(4), 162-170. https://doi.org/10.1089/cell.2023.0019
Mahjoor, M., Afkhami, H., Mollaei, M., Nasr, A., Shahriary, S., Khorrami, S. (2021). MicroRNA-30c delivered by bone marrow-mesenchymal stem cells induced apoptosis and diminished cell invasion in U-251 glioblastoma cell line. Life Sciences, 279, 119643. https://doi.org/10.1016/j.lfs.2021.119643
Almeria, C., Kreß, S., Weber, V., Egger, D., Kasper, C. (2022). Heterogeneity of mesenchymal stem cell-derived extracellular vesicles is highly impacted by the tissue/cell source and culture conditions. Cell & Bioscience, 12(1), 51. https://doi.org/10.1186/s13578-022-00786-7
Afjeh-Dana, E., Naserzadeh, P., Moradi, E., Hosseini, N., Seifalian, A. M., Ashtari, B. (2022). Stem cell differentiation into cardiomyocytes: Current methods and emerging approaches. Stem Cell Reviews and Reports, 18(8), 2566–2592. https://doi.org/10.1007/s12015-021-10280-1
Kou, M., et al. (2022). Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: A next generation therapeutic tool? Cell Death & Disease, 13(7), 580. https://doi.org/10.1038/s41419-022-05034-4
Han, Y., et al. (2022). The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduction and Targeted Therapy, 7(1), 92. https://doi.org/10.1038/s41392-022-00931-1
Hoang, D. M., et al. (2022). Stem cell-based therapy for human diseases. Signal Transduction and Targeted Therapy, 7(1), 272. https://doi.org/10.1038/s41392-022-01134-4
Sarıkaya, A., et al. (2022). Comparison of immune modulatory properties of human multipotent mesenchymal stromal cells derived from bone marrow and placenta. Biotechnic & Histochemistry, 97(2), 79–89. https://doi.org/10.1080/10520295.2021.1877103
Shin, S., et al. (2021). Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton’s jelly. International Journal of Molecular Sciences, 22(2), 845. https://doi.org/10.3390/ijms22020845
Zhang, K., et al. (2021). Comparison of the cytokine profile in mesenchymal stem cells from human adipose, umbilical cord, and placental tissues. Cellular Reprogramming, 23(6), 336–348. https://doi.org/10.1089/cell.2021.0030
Chen, S., et al. (2020). Similar repair effects of human placenta, bone marrow mesenchymal stem cells, and their exosomes for damaged SVOG ovarian granulosa cells. Stem Cells International, 2020, 8861557. https://doi.org/10.1155/2020/8861557
Tai, C., et al. (2021). Analysis of key distinct biological characteristics of human placenta-derived mesenchymal stromal cells and individual heterogeneity attributing to donors. Cells Tissues Organs, 210(1), 45–57. https://doi.org/10.1159/000512596
Kahrizi, M. S., et al. (2023). Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure: A comprehensive review of preclinical studies. Stem Cell Research & Therapy, 14(1), 155. https://doi.org/10.1186/s13287-023-03347-4
Li, C., et al. (2024). Comparison of the therapeutic effects of mesenchymal stem cells derived from human dental pulp (DP), adipose tissue (AD), placental amniotic membrane (PM), and umbilical cord (UC) on postmenopausal osteoporosis. Frontiers in Pharmacology, 15, 1349199. https://doi.org/10.3389/fphar.2024.1349199
Sober, S. A., et al. (2021). Flow cytometric characterization of cell surface markers to differentiate between fibroblasts and mesenchymal stem cells of different origin. Archives of Medical Science, 19(5), 1487–1498. https://doi.org/10.5114/aoms/133701
Jiang, W., & Xu, J. (2020). Immune modulation by mesenchymal stem cells. Cell Proliferation, 53(1), e12712. https://doi.org/10.1111/cpr.12712
Song, N., Scholtemeijer, M., Shah, K. (2020). Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends in Pharmacological Sciences, 41(9), 653–664. https://doi.org/10.1016/j.tips.2020.06.009
Yen, B. L., et al. (2023). Clinical implications of differential functional capacity between tissue-specific human mesenchymal stromal/stem cells. The FEBS Journal, 290(11), 2833–2844. https://doi.org/10.1111/febs.16763
Rodríguez-Fuentes, D. E., et al. (2021). Mesenchymal stem cells current clinical applications: A systematic review. Archives of Medical Research, 52(1), 93–101. https://doi.org/10.1016/j.arcmed.2020.08.007
Tanzadehpanah, H., et al. (2025). Effect of platelet-rich plasma on angiogenic and regenerative properties in patients with critical limb ischemia. Regenerative Therapy, 28, 517–526. https://doi.org/10.1016/j.reth.2024.01.012
Levy, O., et al. (2020). Shattering barriers toward clinically meaningful MSC therapies. Science Advances, 6(30), eaba6884. https://doi.org/10.1126/sciadv.aba6884
Fang, J., et al. (2023). Human placenta-derived mesenchymal stem cell administration protects against acute lung injury in a mouse model. Journal of Cellular Biochemistry, 124(9), 1249–1258. https://doi.org/10.1002/jcb.30489
Ning, K., et al. (2022). Functional heterogeneity of bone marrow mesenchymal stem cell subpopulations in physiology and pathology. International Journal of Molecular Sciences, 23(19), 11928. https://doi.org/10.3390/ijms231911928
Han, X., et al. (2025). Mesenchymal stem cells in treating human diseases: Molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 10(1), 262. https://doi.org/10.1038/s41392-025-01842-1
Bandyopadhyay, S., et al. (2024). Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell, 187(12), 3120–3140.e29. https://doi.org/10.1016/j.cell.2024.05.012
Qin, Y., et al. (2023). An update on adipose-derived stem cells for regenerative medicine: Where challenge meets opportunity. Advanced Science, 10(20), 2207334. https://doi.org/10.1002/advs.202207334
Xu, Z.-H., et al. (2023). Adipokines regulate mesenchymal stem cell osteogenic differentiation. World Journal of Stem Cells, 15(6), 502–515. https://doi.org/10.4252/wjsc.v15.i6.502
Li, J., et al. (2023). The heterogeneity of mesenchymal stem cells: An important issue to be addressed in cell therapy. Stem Cell Research & Therapy, 14(1), 381. https://doi.org/10.1186/s13287-023-03567-8
Meesuk, L., et al. (2022). Osteogenic differentiation and proliferation potentials of human bone marrow and umbilical cord-derived mesenchymal stem cells on the 3D-printed hydroxyapatite scaffolds. Scientific Reports, 12(1), 19509. https://doi.org/10.1038/s41598-022-24058-5
Al-Azab, M., et al. (2022). Aging of mesenchymal stem cell: Machinery, markers, and strategies of fighting. Cellular & Molecular Biology Letters, 27(1), 69. https://doi.org/10.1186/s11658-022-00361-3
Shokati, A., et al. (2024). Good manufacturing practices production of human placental derived mesenchymal stem cells for therapeutic applications: Focus on multiple sclerosis. Molecular Biology Reports, 51(1), 460. https://doi.org/10.1007/s11033-024-09460-7
Harrell, C. R., Volarevic, A., Volarevic, V. (2022). Therapeutic effects of mesenchymal stem cells on cognitive deficits. In Handbook of Stem Cell Therapy (pp. 413–436). Springer. https://doi.org/10.1007/978-3-030-XXXX-X_17
Choudhery, M. S., et al. (2022). Minimum criteria for defining induced mesenchymal stem cells. Cell Biology International, 46(6), 986–989. https://doi.org/10.1002/cbin.11768
Boss, A. L., et al. (2020). Influence of culture media on the derivation and phenotype of fetal-derived placental mesenchymal stem/stromal cells across gestation. Placenta, 101, 66–74. https://doi.org/10.1016/j.placenta.2020.08.007
Ma, H., et al. (2021). Conditioned medium from primary cytotrophoblasts, primary placenta-derived mesenchymal stem cells, or sub-cultured placental tissue promoted HUVEC angiogenesis in vitro. Stem Cell Research & Therapy, 12(1), 141. https://doi.org/10.1186/s13287-021-02226-5
Seok, J., et al. (2020). Mitochondrial dynamics in placenta-derived mesenchymal stem cells regulate the invasion activity of trophoblast. International Journal of Molecular Sciences, 21(22), 8599. https://doi.org/10.3390/ijms21228599
Wang, Y., et al. (2022). Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell, 29(11), 1515–1530. https://doi.org/10.1016/j.stem.2022.10.006
Seok, J., et al. (2023). The dose-related efficacy of human placenta-derived mesenchymal stem cell transplantation on antioxidant effects in a rat model with ovariectomy. Antioxidants, 12(8), 1575. https://doi.org/10.3390/antiox12081575
Kulus, M., et al. (2021). Mesenchymal stem/stromal cells derived from human and animal perinatal tissues—Origins, characteristics, signaling pathways, and clinical trials. Cells, 10(12), 3278. https://doi.org/10.3390/cells10123278
Teoh, P. L., et al. (2023). Human mesenchymal stromal cells derived from perinatal tissues: Sources, characteristics and isolation methods. Malaysian Journal of Medical Sciences, 30(2), 55–70. https://doi.org/10.21315/mjms2023.30.2.5
Gorodetsky, R., Aicher, W. K. (2021). Allogenic use of human placenta-derived stromal cells as a highly active subtype of mesenchymal stromal cells for cell-based therapies. International Journal of Molecular Sciences, 22(10), 5302. https://doi.org/10.3390/ijms22105302
Guo, R., et al. (2022). Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells. Experimental Hematology & Oncology, 11(1), 27. https://doi.org/10.1186/s40164-022-00273-2
Margiana, R., et al. (2022). Clinical application of mesenchymal stem cell in regenerative medicine: A narrative review. Stem Cell Research & Therapy, 13(1), 366. https://doi.org/10.1186/s13287-022-03054-6
